New results from a pre-specified, patient level, pooled analysis from the Phase III DAPA-HF and DELIVER trials demonstrated mortality benefit of Farxiga, compared to placebo, in patients with heart failure (HF).
The reduction in risk of cardiovascular (CV) death was consistent across pre-specified subgroups and is the first analysis to demonstrate a mortality benefit with a HF medication in patients with HF across the left ventricular ejection fraction (LVEF) range.
“Heart failure remains one of the leading causes of death worldwide with high unmet need for some 64 million people. This analysis demonstrates Farxiga’s ability to treat patients across the full left ventricular ejection fraction spectrum and reduce the risk of cardiovascular death,” says Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.
These results were presented at the European Society of Cardiology Congress 2022 in Barcelona, Spain and simultaneously published in Nature Medicine.
The DAPA-HF and DELIVER Phase III trials
The DAPA-HF and DELIVER Phase III trials were randomized and double-blind, comparing Farxiga to placebo. Each trial enrolled patients with a diagnosis of HF, functional limitation, and elevated natriuretic peptides. The principal difference between the two trials was that patients with an LVEF of 40% or less were randomized in DAPA-HF and those with a LVEF greater than 40% in DELIVER. The studies included 11,007 individuals with HF across 20 countries in each trial.
Photo of Mene Pangalos: AstraZeneca